Kornimate/medical-research-clean huggingface dataset:
endocan level in patients with erectile dysfunction and relationship with tadalafil treatment

Conditions: Erectile Dysfunction

Summary: the investigators analyze the patients' endocan levels, iief scores, and hormon levels both before and after tadalafil (5 or 20mg) treatment. the investigators want to see erectile dysfunction severity and tadalafil treatment relations with endocen level.

the investigators will include at least 90 patients in study. blood tests will taken before and after tadalafil treatment and will store at -80 celcius degree.

Eligibility criteria:
inclusion criteria: • patients with erectile dysfuction exclusion criteria: * psychogenic erectile dysfunction * erectile dysfunction associated with hormonal disorders * drug related erectile dysfunction

Keywords: endocan erectile dysfunction tadalafil
safety of elacestrant in er+/her2- and esr1 mutations mbc

Conditions: ESR1 Gene Mutation; Advanced Breast Cancer; Safety

Summary: this study is a prospective non-interventional real-world study enrolling patients with advanced breast cancer who are er+/her2- and have esr1- gene mutations, collecting information on patients' complaints, physical examination, laboratory tests, imaging tests and adverse events to observe the safety of elacestrant treatment.


Eligibility criteria:
inclusion criteria: * 1. must have a histologically or cytologically confirmed diagnosis of breast cancer with evidence of locally advanced disease unsuitable for excision or radical radiotherapy, or evidence of metastatic disease unsuitable for radical treatment. * 2. female ≥ 18 years of age * 3. female subjects must be postmenopausal (meeting any of the following criteria is sufficient) a) has undergone oophorectomy. b) age ≥ 60 years. c) 40 years old \< age ≤ 60 years old with 1 year of menopause. d) age \<60 years and receiving ovarian suppression therapy. * 4. er-positive and her2-negative status and esr1-mutation positive must be confirmed. * 5. must have progressed on at least one line of endocrine therapy prior to enrollment, including monotherapy or combination therapy. * 6. have normal organ function (as assessed by the investigator). exclusion criteria: * 1. women who are pregnant or breastfeeding * 2. known difficulties in tolerating oral medications, or conditions that interfere with the absorption of oral medications or allergies to medications and their excitements * 3. other conditions that make enrollment in the study unsuitable, at the discretion of the investigator
evaluation of blood/imaging based biomarkers, aromatase inhibitor induced musculoskeletal syndrome

Conditions: Aromatase Inhibitor Induced Musculoskeletal Syndrome (AIMSS); Breast Cancer

Summary: this is a pilot trial to evaluate for blood and imaging biomarkers in patients with breast cancer scheduled to start adjuvant hormonal therapy.

this is a prospective single arm study enrolling patients (n = 25) with breast cancer scheduled to start adjuvant hormonal therapy. patients would have completed all their primary treatments (surgery± radiation therapy) and are scheduled to start their adjuvant hormonal therapy. they get baseline blood drawn for oxylipins and sheer wave elastrography (swe) ultrasound of their hands including wrists. they start adjuvant anastrozole and have blood drawn at 3mths and 6mths for measurement of oxylipins. swe ultrasound is repeated at 6mths. this is a pilot trial to evaluate for blood and imaging biomarkers. once pilot data is analyzed, goal is to apply for funding for a larger trial to further evaluate and validate these biomarkers

Eligibility criteria:
inclusion criteria: 1. be capable of understanding the investigational nature of the study and all pertinent aspects of the study 2. be capable of signing and providing written consent in accordance with institutional and federal guidelines 3. have a histologically-confirmed diagnosis of breast cancer 4. be willing and able to comply with scheduled visits, treatment plan, and swe ultrasound imaging 5. age ≥ 21 years 6. post-menopausal women with 1st event of er+ early stage breast cancer (0-3) 7. completed definitive therapy (surgery ± radiation) 8. candidates for adjuvant ai therapy exclusion criteria: 1. have received adjuvant or neo-adjuvant chemotherapy 2. prior endocrine therapy (ai or tamoxifen) 3. history of rheumatoid arthritis or other autoimmune arthritis 4. daily non-steroidal anti-inflammatory drug (nsaid) use (except for daily aspirin use) 5. current use of daily corticosteroids or immunosuppressive therapies

Keywords: aromatase inhibitor induced musculoskeletal syndrome aimss breast cancer biomarkers oxylipin
study of compound edaravone injection for treatment of acute ischemic stroke

Conditions: Acute Ischemic Stroke

Summary: the primary objective of the study is to confirm the efficacy of compound edaravone injection via intravenous infusion every 12 hours in the patients with acute ischemic stroke(ais) in a double-blind, active-controlled manner. the study is also to examine the safety of compound edaravone injection for the ais patients.


Eligibility criteria:
inclusion criteria: * hospitalized patients, diagnosed of ischemic stroke; * onset of stroke is less than or equal to 48 hours; * there are clear signs of neurological deficit: 4≤nihss score≤24, and also, the sum of nihss score for the upper limb and the lower limb is greater than or equal to 2; * patients signed written inform consent exclusion criteria: * cranial ct scan finds intracranial bleeding disorders: hemorrhagic stroke, epidural hematoma, intracranial hematoma, intraventricular hemorrhage, subarachnoid hemorrhage; * iatrogenic stroke; * severe disturbance of consciousness: nihss category 1a for consciousness is greater than 1； * the mrs score prior to this onset is greater than 1; * transient ischemic attack (tia); * sbp after blood pressure control is still greater than or equal to 220 mmhg, or dbp after blood pressure control is still greater than or equal to 120 mmhg; * patients with severe mental disorders and dementia; * alt or ast is greater than 2.0×uln; serum creatinine (scr) is greater than 1.5×uln or creatinine clearance (crcl) is less than 50 ml/min; * therapeutic neuroprotective agents have been applied after onset of stroke, including commercially available edaravone, nimodipine, ganglioside, citicoline, piracetam, butyl benzene peptides, urinary kallidinogenase; * thrombectomy or interventional therapy has been applied or planned after this onset; * patients with malignant tumors or receiving concurrent antitumor treatment; * patients with severe systemic disease, life expectancy is less than 90 days; * allergic to edaravone , taurine or related excipients; * pregnant or lactating women; * have major surgery within 4 weeks before enrollment and not recovered enough to start the study; * participated in other clinical studies within 30 days before randomization; * the investigators consider the patients are not suitable for this trial.
telehealth-based exercise program to treat fatigue in ms

Conditions: Multiple Sclerosis

Summary: this is a clinical trial examining a brief motivational intervention to improve adherence to exercise among individuals with ms to improve fatigue.

this is a 2-arm single blind parallel group rct comparing a brief telephone based motivational intervention to an informational control to improve adherence to exercise among individuals with ms. the primary outcome is improvement in fatigue.

Eligibility criteria:
inclusion criteria: * multiple sclerosis * veteran receiving services in va visn 20 * fatigue * ability to ambulate * cell phone or household phone line * individual with multiple sclerosis verified by ms provider * ambulatory exclusion criteria: * current alcohol dependence or other substance dependence * no working phone

Keywords: multiple sclerosis fatigue exercise telemedicine motivational interviewing counseling depression physical activity
efficacy of ecabet sodium and proton pump inhibitor combination therapy in the treatment of iatrogenic ulcer after endoscopic submucosal dissection

Conditions: Delayed Bleeding,; Healing Ulcer; Quality of Ulcer

Summary: * endoscopic submucosal dissection (esd) is widely indicated to treat gastric adenomas and early gastric cancer (egc).esd is able to obtain en bloc resection of larger specimens. however, esd has more frequent complications (delayed bleeding, ulcer healing, ulcer pain, and etc) due to a more complex procedure. to prevent delayed bleeding, to induce rapid ulcer healing, and to control the ulcer pain acid-suppressing agents (ppi, h2ra) are generally administered. although ppis are widely indicated as first-line drugs for peptic ulcers, ppi drugs are not fully superior to h2ras or other combination drugs for treatment of iatrogenic ulcer healing and delayed bleeding. * ecabet sodium (es)is a widely used mucoprotective agent for the treatment of gastric ulcers. recently, one study showed the additional benefits of using es in combination with the ppi after esd. however, this study did not show the difference of delayed bleeding and the benefit of ulcer pain control. thus, our study prospectively evaluated the difference of delayed bleeding and the benefit of ulcer pain control after esd.


Eligibility criteria:
inclusion criteria: * gastric adenomas or differentiated egc (any size without ulcers or signs of submucosal invasion; intramucosal differentiated-type egc \< 3 cm with a scar; and no lymph node involvement or metastasis by ct) exclusion criteria: * recent use of a ppi, h2ra, bismuth, and antibiotics * current use of aspirin, non-steroidal anti-inflammatory drugs, or corticosteroids * helicobacter pylori infection not evaluated appropriately by endoscopic biopsy and serology * a history of subtotal gastrectomy; patients who underwent surgery due to esd complications; known hypersensitivity to ppis * chronic co-morbid disease, such as chronic liver and renal disease
lunatocapitate fusion versus four-corner fusion for snac and slac arthritis.

Conditions: Wrist Arthritis

Summary: hypothesis: lunate-capitate-fusion (lcf) results in comparable outcome (i.e. not worse) to four-corner-fusion (4cf) for scaphoid nonunion advanced collapse (snac) and scapholunate advanced collapse (slac) arthritis regarding functional results (grip strength). design: prospective randomised comparison. inclusion criteria: snac or slac arthritis requiring a salvage procedure (grade 2-3). exclusion criteria: snac or slac arthritis grade 4 (panarthritis). inability to co-operate with the follow-up protocol (language difficulties, severe psychiatric disorder or drug addiction).

surgical method: patient will be operated in axially plexus with a dorsal approach through the 3d and 4th extensor tendon compartments. the wrist joint capsule will be opened with a berger incision. after excision of the scaphoid and preparation of the articular surfaces to be fused, the bones will be fixated with k-wires. bone autograft from the scaphoid, crista or radius will be used according to the surgeon's preference based on the condition of the fusion surfaces. the wrist be immobilized in a short arm plaster cast until the fusions are radiologically healed after10-12 weeks. the k-wires will be extracted in local anesthesia after another 2-6 weeks. sample size: this study will have a power of 80% to show that the mean grip strength for lc fusion is as least as high as the mean for 4cf (non-inferiority). this assumes that the means for the lc fusion and the 4cf are equal (at 70% of the uninjured side) with a common within-group standard deviation of 14 (salzman et al. 2015), that a difference of 10% or less is unimportant, that the sample size in the two groups will be 25 and 25, and the alpha (1 tailed) is set at 0,05.formally, the null hypothesis is that the mean for lunocapitate fusion is 10% lower than the mean for 4cf, and that the study has power of 80,1% to reject this null. equivalently, the likelihood is 80,1% that the 95% confidence interval for the mean difference will exclude a difference of 10% in favor of 4cf. we aim to include 60 patients to cover for a certain loss to follow-up. assessment: patients will be assessed regarding range of motion and grip strength and complete the dash and prwe questionnaires before surgery (baseline) and 1 and 2 years postoperatively. radiology: plain anterior and lateral radiographs will be obtained 1 and 2 years postoperatively for purpose of the study. according to the standard treatment protocol, clinical and radiological healing assessment will be conducted 10-12 weeks postoperatively. radiographs will be analyzed by a radiologist. complications will be recorded 1 and 2 years postoperatively. analyzes: the mann-whitney and chi-square tests will be used for non-parametric data (dash, prwe and presence of arthritis and complications). t-test will be used for numerical data (rom, grip strength).

Eligibility criteria:
inclusion criteria: - snac or slac arthritis grade 2-3 exclusion criteria: * snac or slac arthritis grade 4 * inability to cooperate with the follow-up protocol
the influence of dimensional anatomic variables on the outcomes of maxillary sinus grafting procedures

Conditions: Edentulism; Alveolar Bone Atrophy; Sinus Pneumatization

Summary: the hypothesis of this study is that there is a significant difference in bone maturation after sinus grafting determined by the distance from the buccal to the palatal wall of this cavity.

inadequate alveolar bone height as a consequence of tooth loss is a common limitation for properly placing endosseous dental implants in the posterior maxilla. grafting of the maxillary sinus has been regarded as one of the most reliable surgical alternatives to correct this problem. several sinus grafting techniques, using different materials, have been reported showing high survival rates. however, there are many factors that may alter the outcomes of this procedure. the maturation and consolidation of the grafted area relies on the proper formation of a functional graft-vital bone complex. this maturation process requires an adequate migration of osteogenic cells from native bone, that could be limited in situations where the dimensions of the maxillary sinus are excessive. hence, the purpose of this research project is to determine the influence of the distance from the lateral to the medial wall of the maxillary sinus on the outcomes of a sinus augmentation procedures performed using the lateral approach using clinical, radiographic and histomorphometric analysis.

Eligibility criteria:
inclusion criteria: * adults patients (older than 18 years), up to 85 years-old. * physical status according to the american society of anesthesiologists (asa) i or ii * patient in need of a sinus grafting using the lateral approach to allow the proper placement of dental implants. the remaining bone height must be 3 mm or less. * no uncontrolled systemic disease or condition known to alter bone metabolism * adequate oral hygiene (o'leary plaque score ≤20%) exclusion criteria: * long term (\>2 weeks) use of antibiotics in the past 3 months * patients smoking more than half-pack a day * patients taking medications known to modify bone metabolism (such as bisphosphonates, corticosteroids, etc...) * pregnant or attempting to get pregnant * patients that don't meet the indications for sinus grafting (existing sinus conditions, sepsis, history of cancer and/or radiation to the oral cavity, use of biphosphonates, pregnancy), or have postoperative complications related to those conditions.

Keywords: implant site development bone grafting dental implants
comparison of partial removal and total removal of the corneal epithelium on keratoconus

Conditions: Keratoconus

Summary: the purpose of this study is to determine which surgical method makes less corneal haze

keratoconus is an asymmetric, bilateral, progressive non-inflammatory ectasia of the cornea. the investigators evaluate whether partial removal versus total removal of the corneal epithelium can lead to less corneal haze and better visual outcomes.

Eligibility criteria:
inclusion criteria: * age between 16-40 years * axial topography consistent with keratoconus * minimum corneal thickness more than 400 µm and a progression of keratoconus in past 12 months exclusion criteria: * history of ocular herpes or non-healing corneal ulcers * subjects with current ocular infection * severe preoperative corneal haze or scar * severe ocular surface disease * autoimmune diseases * pregnant women

Keywords: keratoconus remove cornea visual acuity
incidence of fat embolism with computer assisted total knee arthroplasty

Conditions: Fat Embolism Syndrome

Summary: the study to determine the if the incidence of fat embolism is decreased using computer assisted technology when performing a total knee arthroplasty.

computer assisted total knee arthroplasty is at its inception currently. there are many unknowns about this specific technique, particularly when it comes down to fat embolism syndrome. there is a high incidence of fat embolism during total knee arthroplasty as seen both by echocariography as well as sampling of right atrial blood. during a jig-based, or traditional, total knee arthroplasty, a rod is placed inside the femur, and sometimes the tibia as well. intrusumentations of the medullary canal is known to cause fat embolism. fat embolism is a syndrome which can produce post-operative confusion, hypoxemia, all the way to post-op and intra-operative death. computer assisted total knee arthroplasty does not use intramedullary jigs. it is presumed that by not instrumenting the medullary canal, the rate of fat embolism will be significantly reduced. fifty patient s will be studied while they are having a computer assisted total knee arthoplasty. a picc line will be placed in their arm by an interventional radiologist pre-operatively. this picc line will be thread into the right atrium. right atrial blood will be sent to pathology every 10 minutes during the 60 to 90 minute procedure and at intervals post-op. the right atrial blood will be stained for bone marrow elements. this study is to presumed to show yet another benefit of computer assisted surgery.

Eligibility criteria:
inclusion criteria: * must be a candidate for computer assisted total knee arthroplasty exclusion criteria: * mentally incompetent patients excluded

Keywords: fat embolism total knee arthroplasty
effect of resveratrol on age-related insulin resistance and inflammation in humans

Conditions: Type 2 Diabetes Mellitus; Insulin Resistance

Summary: resveratrol is a natural polyphenol (a compound containing a phenol functional group) that can be found in many plants. the purpose of this research is to study the effects of resveratrol on the action of insulin (a hormone produced in the body by the pancreas that regulates the amount of sugar in the blood), fat accumulation, and inflammation in the body.

participants will meet with the study team to discuss dietary recommendations. each participant will be instructed to follow a standardized diet plan and to avoid vigorous exercise before beginning the study. participants will be given a 28 day supply of resveratrol capsules (two 500 mg capsules taken twice a day). a comprehensive study of whole-body insulin action called a pancreatic clamp will be done and small samples of fat and muscle will be taken before and after the administration of resveratrol.

Eligibility criteria:
inclusion criteria: * bmi: 26-35 * non-smoker * normal screening labs (cmc, chemistry, lfts pt/ptt) * no cad * good iv access exclusion criteria: * high cholesterol * \<4 week history of participation in another drug trial * severe hypertension * heart disease * liver disease of liver abnormalities * cerebrovascular disease, i.e. stroke * cvd * seizures * bleeding disorders * muscle disease * cancer * hiv * hepatitis (all types) * mentally disabled persons * pregnant women * allergies to novocaine, lidocaine, benzocaine * subjects on the following medications: * anticoagulant and antiplatelet drugs * anti-epileptic drugs * mexiletene * quinidine * cyclosporine * tacrolimus * hiv protease inhibitors

Keywords: diabetes mellitus, type 2 glucose metabolism disorders metabolic diseases diabetes mellitus endocrine system diseases resveratrol therapeutic uses
tranexamic acid for second trimester dilation and evacuation and bleeding outcomes

Conditions: Abortion; Dilation and Evacuation; Hemorrhage; Prophylactic Tranexamic Acid Use; Blood Loss

Summary: although procedural abortion in the second trimester is extremely safe, hemorrhage is one of the leading causes of morbidity and mortality. tranexamic acid (txa) is used commonly in obstetrics to prevent or manage intrapartum or postpartum hemorrhage and has been associated with decreased mortality and decreased blood loss at the time of birth. some guidelines are recommending the use of txa for both the prevention and management of bleeding for abortion care. however, there are currently no published studies assessing the association between txa and bleeding outcomes for abortion procedures. this study will involve a randomized, placebo-controlled trial of pregnant patients aged 18 and older desiring dilation and evacuation (d\&e) for abortion or fetal demise at 18-24 weeks gestation. the primary aim is to determine whether prophylactic txa has an effect on the need for additional interventions to control bleeding at the time of d\&e. the secondary aim is to determine whether prophylactic txa has an effect on the mean quantitative procedural blood loss.


Eligibility criteria:
inclusion criteria: * able to understand and sign informed consent * speaks english or spanish language, * requesting pregnancy termination or procedural management of fetal demise - intrauterine pregnancy, 18 weeks 0 days and 24 weeks and 0 days gestation exclusion criteria: * history of or current thromboembolic event (deep vein thrombosis, stroke, pulmonary embolism) * history of coagulopathy * anticoagulant use in the preceding five days * severe renal impairment * chorioamnionitis or sepsis * suspected placenta accreta spectrum * prophylactic uterotonics other than oxytocin given (or planned to be given) at the start of the d\&e * known allergic reaction or hypersensitivity to txa

Keywords: abortion dilation and evacuation txa hemorrhage tranexamic acid d&e